Loading company…
Neusignal Therapeutics develops small-molecule treatments for dementia and other central nervous system diseases.
Founded in 2022, Neusignal Therapeutics is a Tokyo-based biotechnology company developing drugs for dementia and mental disorders, with a focus on Alzheimer's disease. Its small-molecule drug research aims to support treatment of central nervous system diseases. In March 2024, it raised JPY 1.33 billion in seed funding led by Fast Track Initiative, Keio Innovation Initiative, Mizuho Capital, Mitsubishi UFJ Capital, and SMBC Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in